- Home
- USEA vs KAPA Comparison
USEA vs KAPA Comparison
Compare USEA & KAPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- KAPA
- Stock Information
- Founded
- USEA 2004
- KAPA 2013
- Country
- USEA Greece
- KAPA United States
- Employees
- USEA N/A
- KAPA N/A
- Industry
- USEA Marine Transportation
- KAPA
- Sector
- USEA Consumer Discretionary
- KAPA
- Exchange
- USEA Nasdaq
- KAPA NYSE
- Market Cap
- USEA 10.5M
- KAPA 10.8M
- IPO Year
- USEA N/A
- KAPA 2024
- Fundamental
- Price
- USEA $1.57
- KAPA $0.92
- Analyst Decision
- USEA
- KAPA Strong Buy
- Analyst Count
- USEA 0
- KAPA 3
- Target Price
- USEA N/A
- KAPA $8.33
- AVG Volume (30 Days)
- USEA 23.4K
- KAPA 13.5M
- Earning Date
- USEA 08-12-2025
- KAPA 08-23-2025
- Dividend Yield
- USEA 2.56%
- KAPA N/A
- EPS Growth
- USEA N/A
- KAPA N/A
- EPS
- USEA N/A
- KAPA N/A
- Revenue
- USEA $42,595,000.00
- KAPA N/A
- Revenue This Year
- USEA N/A
- KAPA N/A
- Revenue Next Year
- USEA $11.62
- KAPA N/A
- P/E Ratio
- USEA N/A
- KAPA N/A
- Revenue Growth
- USEA N/A
- KAPA N/A
- 52 Week Low
- USEA $1.00
- KAPA $0.40
- 52 Week High
- USEA $2.78
- KAPA $4.00
- Technical
- Relative Strength Index (RSI)
- USEA 53.73
- KAPA N/A
- Support Level
- USEA $1.56
- KAPA N/A
- Resistance Level
- USEA $1.61
- KAPA N/A
- Average True Range (ATR)
- USEA 0.08
- KAPA 0.00
- MACD
- USEA -0.01
- KAPA 0.00
- Stochastic Oscillator
- USEA 67.70
- KAPA 0.00
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.
About KAPA KAIROS PHARMA LTD
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.